Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT3 | P40763 | 1/20 | 0.58 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.55 |
| ▸ | POLA1 | P09884 | 2/20 | 0.48 |
| ▸ | CDK1 | P06493 | 2/20 | 0.48 |
| ▸ | TMIGD3 | P0DMS9 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | HTR2B | P41595 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.44 |
| ▸ | APP | P05067 | 1/20 | 0.44 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.43 |
| ▸ | IP6K3 | Q96PC2 | 1/20 | 0.43 |
| ▸ | IP6K2 | Q9UHH9 | 1/20 | 0.43 |
| ▸ | CDC7 | O00311 | 1/20 | 0.43 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.43 |
| ▸ | MGMT | P16455 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16146883 | 0.85 | TMIGD3 (0.65) | PIN1POLA1CDK1TMIGD3HTR2C | |
| SCHEMBL16146393 | 0.85 | STAT3 (0.60) | STAT3PIN1CDK1TMIGD3HTR2C | |
| SCHEMBL16146547 | 0.85 | PAK4 (0.60) | STAT3POLA1CDK1TMIGD3HTR2C | |
| SCHEMBL16146202 | 0.85 | CDK1 (0.48) | STAT3POLA1CDK1TMIGD3HTR2C | |
| SCHEMBL16146760 | 0.85 | PRMT1 (0.56) | STAT3PIN1POLA1CDK1MAPT | |
| SCHEMBL14939010 | 0.84 | CDK1 (0.65) | PIN1POLA1CDK1LMNACYP1A2 | |
| SCHEMBL16146972 | 0.82 | CDK1 (0.73) | STAT3PIN1CDK1TMIGD3HTR2C | |
| SCHEMBL16146402 | 0.81 | CYP1A2 (0.46) | STAT3PIN1TMIGD3CYP1A2MAPT | |
| SCHEMBL16145956 | 0.79 | STAT3 (0.64) | STAT3PIN1CDK1TMIGD3HTR2C | |
| SCHEMBL16147160 | 0.79 | ALPL (0.50) | STAT3POLA1CDK1TMIGD3HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140303112-A1 | Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) | ENERGENESIS BIOMEDICAL CO., LTD (TW) | 2014-10-09 | — | — | US | claimed |
| US-9938279-B2 | Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) | ENERGENESIS BIOMEDICAL CO., LTD (TW) | 2018-04-10 | — | — | US | disclosed |
| US-20140303112-A1 | Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) | ENERGENESIS BIOMEDICAL CO., LTD (TW) | 2014-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140303112-A1 | Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) | PRKAG2, PRKAB2, PRKAG1 | STAT3 990/4885PIN1 4585/4885POLA1 2876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.